Apply to Cambridge Angels

Apply to Cambridge Angels

PhoreMost makes key appointments to Board to advance development of next-generation degrader therapeutics

7 May

Written By Alexandra Collingbourne

Alexandra Collingbourne

Archer enters partnership with Paragraf for Biochip development

Rein Therapeutics and Qureight Ltd Announce Planned Integration of Deep-Learning Platform for Phase 2 Trial of LTI-03 in Patients with IPF